Astellas Pharma(FRA) YPH

Market Cap€22.23B

Since IPON/A

5 YearN/A

1 YearN/A

1 MonthN/A

€12.40

+0.00%

+0.00Today

Astellas Pharma Financials at a Glance

Market Cap

€22.23B

Revenue (TTM)

€12.62K

Net Income (TTM)

€2.02K

EPS (TTM)

€1.13

P/E Ratio

10.99

Dividend

€0.44

Beta (Volatility)

0.01 (Low)

Dividend

€0.44

Beta (Volatility)

0.01 (Low)

Price

€12.40

Volume

430

Open

€13.00

Price

€12.40

Volume

430

Open

€13.00

Previous Close

€12.40

Daily Range

€12.40 - €13.00

52-Week Range

€8.56 - €14.19

Estimated Earnings Date

N/A

Dividend

€0.44

Beta (Volatility)

0.01 (Low)

Price

€12.40

Volume

430

Open

€13.00

Previous Close

€12.40

Daily Range

€12.40 - €13.00

52-Week Range

€8.56 - €14.19

Estimated Earnings Date

N/A

YPH News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Astellas Pharma

Astellas Pharma, Inc. engages in the research, development, manufacture, import, and export of pharmaceutical products. Its products focus on therapeutic fields that include transplantation, immunology, infectious diseases, urology, oncology, neuroscience, diabetic complications, and metabolic diseases. The firm's global brands include Prograf, Vesicare, Protopic, Harnal, and Funguard. The company was founded by Kenji Yamanouchi in April 1923 and is headquartered in Tokyo, Japan.

Industry

Pharmaceuticals

Sector

Health Care

Employees

14,099

CEO

Naoki Okamura

Website

www.astellas.com

YPH Financials

Key Financial Metrics (TTM)

Gross Margin

N/A

Operating Margin

N/A

Net Income Margin

N/A

Return on Equity

21.06%

Return on Capital

N/A

Return on Assets

N/A

Earnings Yield

9.10%

Dividend Yield

3.53%

Payout Ratio

N/A

Stock Overview

Market Cap

€22.23B

Shares Outstanding

1.79B

Volume

430

Avg. Volume

62.924

Financials (TTM)

Gross Profit

N/A

Operating Income

N/A

EBITDA

N/A

Operating Cash Flow

N/A

Capital Expenditure

N/A

Free Cash Flow

N/A

Cash & ST Invst.

N/A

Total Debt

N/A

Astellas Pharma Performance Analysis

Astellas Pharma annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2023	2023-03-31	EUR 10,777,094,369	8.5%
2024	2024-03-31	EUR 10,241,857,073	-5.0%
2025	2025-03-31	EUR 11,684,421,833	14.1%
2026	2026-03-31	EUR 12,251,534,518	4.9%

Astellas Pharma annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2023	2023-03-31	EUR 0.38	-25.3%
2024	2024-03-31	EUR 0.06	-84.2%
2025	2025-03-31	EUR 0.17	185.1%
2026	2026-03-31	EUR 0.93	438.6%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q2 2026YOY CHG

Revenue

€3.46K

+1.1%

Gross Profit

€2.60K

+1.1%

Gross Margin

75.29%

+1.0%

Market Cap

€22.23B

N/A

Market Cap/Employee

€1.47

N/A

Employees

14,099

N/A

Net Income

€765.06

+1.8%

EBITDA

€1.27K

+1.3%

Quarterly Fundamentals

Name

Q2 2026YOY CHG

Total Cash

€4.49K

-31.1%

Total Debt

€3.17K

+0.6%

Accounts Receivable

€4.48K

+1.1%

Inventory

€1.82K

+1.0%

Long Term Debt

€1.72K

+0.5%

Short Term Debt

€1.45K

+0.7%

Return on Assets

10.22%

+4.2%

Return on Invested Capital

6.31%

+1.2%

Free Cash Flow

€404.86

+1.5%

Operating Cash Flow

€472.94

+1.4%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

^GSPCS&P 500

^GSPCS&P 500$7,684.24-0.00%

^DJIDJI

^DJIDJI$53,254.61-0.01%

^IXICNASDAQ

^IXICNASDAQ$26,319.55-0.00%

BTCBitcoin

BTCBitcoin$78,890.00-0.00%

SPCXSPCX

SPCXSPCX$142.81+0.01%

AAPLAAPL

AAPLAAPL$315.25-0.01%

AMZNAMZN

AMZNAMZN$258.45-0.03%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

PCGPG&E

PCGPG&E$13.27-0.20%

NVDANvidia

NVDANvidia$220.78+0.01%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF$9.97+0.11%

CNHCNH Industrial

CNHCNH Industrial$11.83+0.01%

NUNu Holdings

NUNu Holdings$14.55+0.02%

BITOProShares Trust - ProShares Bitcoin ETF

BITOProShares Trust - ProShares Bitcoin ETF$10.63+0.02%

AALAmerican Airlines Group

AALAmerican Airlines Group$13.43-0.02%

Questions About YPH

What is the current price of Astellas Pharma?

Astellas Pharma is trading at €12.40 per share.

What is the 52-week range for Astellas Pharma?

Over the past 52 weeks, Astellas Pharma has traded between €8.56 and €14.19.

How much debt does Astellas Pharma have?

As of the most recent reporting period, Astellas Pharma reported total debt of €3.17B.

How much cash does Astellas Pharma have on hand?

Astellas Pharma reported €1.32B in cash and cash equivalents in its most recent financial results.

What is Astellas Pharma’s dividend yield?

Astellas Pharma currently has a dividend yield of 3.53%.

Astellas Pharma(FRA) YPH

Astellas Pharma Financials at a Glance

YPH News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Astellas Pharma

YPH Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Astellas Pharma Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About YPH

What is the current price of Astellas Pharma?

What is the 52-week range for Astellas Pharma?

How much debt does Astellas Pharma have?

How much cash does Astellas Pharma have on hand?

What is Astellas Pharma’s dividend yield?

Premium Investing Services